CJC-1295 (No DAC) 30mg — Vial Spec, Reconstitution Math & COA

Overview of CJC-1295 (No DAC) 30mg Mass Specification

A 30mg vial of CJC-1295 (No DAC) contains 30 milligrams of lyophilized synthetic peptide, chemically designated as Modified GRF (1-29). This specific mass format is engineered primarily for institutional laboratories, automated microplate dispensers, and large-scale longitudinal rodent studies where preparing frequent low-mass stock solutions introduces unwanted inter-assay variability.

While PX1 Research routinely stocks standard individual unit sizes such as 2mg and 5mg on our all peptides catalog to preserve bioactivity for smaller assay cohorts, high-mass specifications like 30mg are evaluated under identical production parameters. For researchers assessing standard catalog formats, our CJC-1295 (No DAC) product page details currently available stock sizes. High-mass configurations deliver a singular, highly uniform stock lot for extensive trial matrices, ensuring consistent receptor exposure across prolonged testing schedules.

Biochemical Identity and Receptor Binding Kinetics

CJC-1295 (No DAC), also classified as Tetrasubstituted Modified GRF (1-29), is a 29-amino-acid peptide derivative of endogenous growth hormone-releasing hormone (GHRH). Its primary sequence—Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2—features four strategic amino acid substitutions at positions 2, 8, 15, and 27. These modifications significantly enhance resistance to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) compared to native GHRH(1-29).

Preclinical studies suggest that CJC-1295 (No DAC) selectively targets and activates the GHRH receptor on anterior pituitary somatotrophs. In vitro binding assays demonstrate that this binding event activates adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and triggering pulsatile growth hormone (GH) release. Because it lacks the Drug Affinity Complex (DAC) Lys(maleimidopropionyl) addition, CJC-1295 (No DAC) does not covalently bind to serum albumin, resulting in a plasma half-life of approximately 30 minutes in rodent models. This rapid clearance profile preserves natural physiological GH pulsatility without inducing continuous, non-physiological baseline elevations.

30mg Reconstitution Math and Concentration Calculations

Accurate volumetric reconstitution of a 30mg vial requires precise diluent measurement to establish targeted working concentrations for micro-pipetting. Because 30,000 micrograms (µg) of active peptide are present in a 30mg mass, adding small diluent volumes yields high stock concentrations suited for master-mix preparations or automated diluents.

When reconstituting 30mg of lyophilized powder, the resulting concentration matrix follows standard linear dilution formulas:

1.0 mL Diluent Volume: Reconstituting 30mg with 1.0 mL of diluent yields a final stock concentration of 30 mg/mL (or 30 µg/µL). A standard 10 µL laboratory pipette aliquot delivers precisely 300 µg of active compound.

2.0 mL Diluent Volume: Reconstituting 30mg with 2.0 mL of diluent yields a stock concentration of 15 mg/mL (or 15 µg/µL). In this configuration, a 10 µL aliquot contains 150 µg of active compound.

3.0 mL Diluent Volume: Adding 3.0 mL of diluent produces a final concentration of 10 mg/mL (or 10 µg/µL), where each 10 µL volume contains 100 µg of peptide.

To verify custom laboratory dilutions or adapt calculations for alternative target concentrations, researchers can utilize our interactive reconstitution calculator tool.

Aliquot Planning and Storage Protocols for High-Mass Fills

Managing a 30mg peptide vial requires a structured aliquot strategy to prevent potency loss caused by repeated freeze-thaw cycles or prolonged aqueous exposure. Hydrolysis and peptide aggregation accelerate when reconstituted proteins remain in liquid state at elevated temperatures.

Upon initial reconstitution using 0.9% Benzyl Alcohol Bacteriostatic Water or Sterile Water for Injection, the primary stock solution should be divided immediately into single-use microcentrifuge tubes (e.g., 50 µL to 200 µL aliquots) under aseptic laminar flow conditions. Lyophilized vials stored long-term should be maintained at -20°C or -80°C in a desiccated environment. Reconstituted aliquots designated for immediate use within 14–28 days must be stored at 2°C to 8°C. Sub-aliquots intended for extended experimental timelines should be flash-frozen and kept at -80°C until immediately prior to assay administration.

Selecting Optimal Mass Formats: 30mg vs. Standard 2mg / 5mg Vials

Selecting the correct vial size depends entirely on the design, scale, and throughput of the research protocol. A 30mg vial is optimized for high-volume settings, such as multi-subject animal studies, microplate screening platforms, or core facilities running concurrent assays where batch-to-batch consistency across multiple plates is critical.

Conversely, smaller formats—such as 2mg or 5mg single vials—are preferred for low-throughput pilot studies, limited in vitro assays, or initial dose-response mapping. Utilizing smaller unit sizes minimizes the duration that reconstituted peptide remains in liquid storage, reducing the risk of enzymatic or hydrolytic degradation. Investigators running small research cohorts typically achieve superior experimental control by procuring multi-vial packs of standard mass sizes rather than opening a single 30mg mass fill.

Quality Control Standards: Analytical HPLC, MS, and COA Issuance

PX1 Research mandates strict analytical testing for every production lot to guarantee research reproducibility. Every lot of CJC-1295 (No DAC) undergoes rigorous characterization in an ISO 17025 accredited laboratory prior to release.

Purity is quantified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum chemical purity of ≥98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the precise molecular weight of 3367.9 Da, verifying identity and the absence of truncated sequences or manufacturing impurities. Additionally, every fill undergoes Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly below <0.01 EU/mg, protecting cell cultures and animal models from inflammatory artifacts. Researchers can view and download lot-specific documentation directly via our public certificate of analysis repository.

Comparative Analysis: CJC-1295 (No DAC) vs. Related GHRH Analogs

Understanding the differences between CJC-1295 (No DAC) and other GHRH analogs or secretagogues is critical for accurate experimental design. The table below outlines key structural, pharmacokinetic, and functional properties across related research compounds:

CJC-1295 (No DAC) maintains a 30-minute half-life, providing discrete, pulsatile signaling without long-term plasma accumulation. In contrast, CJC-1295 with DAC includes a maleimide complex that binds native albumin, extending its terminal half-life to several days in rodent models and creating continuous GHRH-R activation. Unmodified GHRH fragments like Sermorelin feature a shorter 8–12 minute half-life due to rapid DPP-IV cleavage, while non-peptidic or ghrelin-receptor agonists such as Ipamorelin target the Growth Hormone Secretagogue Receptor (GHSR-1a) rather than the GHRH receptor. Comparative data across these pathways can be further explored within our growth hormone research library.

Preclinical Research Applications and Mechanistic Findings

In vitro and animal model studies have evaluated CJC-1295 (No DAC) across several physiological domains involving the GH/IGF-1 axis. Because growth hormone plays an integral role in cellular proliferation, protein translation, and tissue remodeling, GHRH analogs serve as important tool compounds in metabolic research.

Preclinical data indicate that systematic administration of CJC-1295 (No DAC) in rodent models leads to measurable increases in circulating serum IGF-1 levels. This systemic elevation is associated with enhanced skeletal muscle protein synthesis rates, accelerated nitrogen retention, and increased collagen mRNA expression in connective tissue models. Furthermore, researchers utilizing murine models of metabolic dysregulation have observed improvements in lipid oxidation patterns and body composition parameters without triggering desensitization of the pituitary GHRH receptor during intermittent pulse protocols.

Handling Protocols and Aseptic Preparation Technique

Maintaining peptide integrity during reconstitution requires strict adherence to laboratory protocols. Lyophilized cakes of CJC-1295 (No DAC) should be allowed to equilibrate to room temperature inside a desiccator before reconstitution to prevent moisture condensation on the cake surface.

When introducing diluent (such as 0.9% Benzyl Alcohol Bacteriostatic Water), direct the stream against the glass vial wall rather than spraying directly onto the lyophilized powder. Gently swirl the vial in a circular motion until fully dissolved. Rapid shaking or vigorous vortexing must be avoided, as shear forces at the air-water interface can cause peptide denaturation, surface aggregation, or irreversible precipitation. Reconstitution should always take place inside a certified laminar flow hood utilizing sterile, pyrogen-free laboratory consumables.

Institutional Procurement and Supply Chain Logistics

PX1 Research operates dedicated manufacturing and distribution facilities based entirely in the United States, shipping orders directly from our California and Arizona hubs. Standardized processing guarantees same-day dispatch for orders placed before cutoff times (Monday through Friday), ensuring minimal transit delays for temperature-sensitive compounds.

For academic departments, contract research organizations (CROs), and industrial laboratories requiring ongoing bulk supply, high-mass lots, or custom lyophilized fill sizes, detailed procurement parameters are available through our wholesale portal. Researchers seeking additional technical literature on signal transduction pathways are encouraged to visit the centralized PX1 research hub.